Bruker Corporation BRKR
61.59 USD +1.26 (+2.09%)
At closeNov 13, 2026, 4:00 PM EST
61.59 0.00 0.00%
After hours · Nov 13, 4:00 PM ET
59.13 Day range 61.94
32.76 52-week range 66.54
- YTD
- +30.74%
- 1 year
- +47.38%
News
zacks.com Should You Continue to Retain Bruker Stock in Your Portfolio? BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.
benzinga.com Citigroup Maintains Neutral on Bruker, Raises Price Target to $64 Citigroup analyst Albert Hu maintains Bruker (NASDAQ:BRKR) with a Neutral and raises the price target from $53 to $64.
benzinga.com Leerink Partners Maintains Outperform on Bruker, Raises Price Target to $85 Leerink Partners analyst Puneet Souda maintains Bruker (NASDAQ:BRKR) with a Outperform and raises the price target from $80 to $85.
benzinga.com Wayfair, Lendingtree, Bruker, Zimmer Biomet And Other Big Stocks Moving Higher On Wednesday U.S. stocks surged, led by Wayfair after strong results; Cricut, Array Technologies, Clear Secure and others also posted double-digit gains.
benzinga.com Bruker Q3 2026 Earnings Call Transcript Bruker (NASDAQ:BRKR) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Bruker Q3 Adj. EPS $0.56 Beats $0.42 Estimate, Sales $874.000M Beat $868.827M Estimate Bruker (NASDAQ:BRKR) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.42 by 33.33 percent. This is a 24.44 percent increase over earnings of $0.45 per…- benzinga.com Bruker Affirms FY2026 Adj EPS Guidance of $2.10-$2.15 vs $2.12 Est; Lowers FY2026 Sales Guidance from $3.540B-$3.570B to $3.520B-$3.560B vs $3.556B Est Bruker (NASDAQ:BRKR) affirms FY2026 Adj EPS guidance from $2.10-$2.15 to $2.10-$2.15 vs $2.12 analyst estimate. Lowers FY2026 sales outlook from $3.540 billion-$3.570 billion to $3.520 billion-$3.560…
benzinga.com SpaceX Jumps 10%, Nasdaq 100 Rises as AI Trade Returns: Stock Market Today SpaceX's blowout third quarter and Super Micro's guidance hike revive the AI trade, lifting the Nasdaq 100 as Netflix and AT&T slide on results.
benzinga.com This Chemours Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday Analysts downgraded CTNM, CC, ACI, BRKR and SAFE; targets fell for CTNM, CC and ACI, while BRKR received a new $60 target.
benzinga.com JP Morgan Downgrades Bruker to Neutral, Announces $60 Price Target JP Morgan analyst Casey Woodring downgrades Bruker (NASDAQ:BRKR) from Overweight to Neutral and announces $60 price target.
benzinga.com TD Cowen Maintains Hold on Bruker, Raises Price Target to $62 TD Cowen analyst Kyle Boucher maintains Bruker (NASDAQ:BRKR) with a Hold and raises the price target from $60 to $62.
benzinga.com Barclays Maintains Overweight on Bruker, Raises Price Target to $70 Barclays analyst Luke Sergott maintains Bruker (NASDAQ:BRKR) with a Overweight and raises the price target from $58 to $70.- benzinga.com Guggenheim Maintains Buy on Bruker, Raises Price Target to $72 Guggenheim analyst Subbu Nambi maintains Bruker (NASDAQ:BRKR) with a Buy and raises the price target from $70 to $72.
benzinga.com Leerink Partners Maintains Outperform on Bruker, Raises Price Target to $80 Leerink Partners analyst Puneet Souda maintains Bruker (NASDAQ:BRKR) with a Outperform and raises the price target from $60 to $80.
benzinga.com Bruker Wins Major UC Berkeley Order For Advanced Research Systems Bruker Corporation (NASDAQ:BRKR) today announced a multi-system order from the University of California, Berkeley for high-field Nuclear Magnetic Resonance (NMR) instrumentation at the Pines Magnetic…
benzinga.com LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday U.S. stocks mixed as Nasdaq rises; LuxExperience jumps 13.5% on strong sales, while Einride, Forgent, Cipher and others post gains.- benzinga.com UBS Maintains Neutral on Bruker, Raises Price Target to $65 UBS analyst Dan Leonard maintains Bruker (NASDAQ:BRKR) with a Neutral and raises the price target from $45 to $65.
- benzinga.com Bruker, Luvata Team Up To Boost Superconductor Supply For Fusion Power Projects Bruker Energy & Supercon Technologies (BEST), a segment of Bruker Corporation (NASDAQ:BRKR), and Luvata Materials & Solutions, a Business Unit of Luvata Group (LUVATA) today announced a strategic…
benzinga.com Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit 10x Genomics won a $4.8 million patent infringement lawsuit against Qiagen subsidiary Parse Biosciences, prompting plans for an injunction.- benzinga.com Citigroup Maintains Neutral on Bruker, Lowers Price Target to $53 Citigroup analyst Brendan Digan maintains Bruker (NASDAQ:BRKR) with a Neutral and lowers the price target from $60 to $53.
benzinga.com S&P 500 Hits Record Highs, Palantir Jumps 27%: Stock Market Today The S&P 500 and Dow set records as Palantir and Caterpillar earnings powered chips higher, while crude slid 5%.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 415.3% to $18.81 during Tuesday's regular session. The company's market cap stands at $1.9 million. Adagio Medical Holdings (NASDAQ:ADGM) shares…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. Adagio Medical Holdings…
- benzinga.com Bruker Affirms FY2026 Adj EPS Guidance of $2.10-$2.15 vs $2.12 Est; Lowers FY2026 Sales Guidance from $3.570B-$3.600B to $3.540B-$3.570B vs $3.589B Est Bruker (NASDAQ:BRKR) affirms FY2026 Adj EPS guidance from $2.10-$2.15 to $2.10-$2.15 vs $2.12 analyst estimate. Lowers FY2026 sales outlook from $3.570 billion-$3.600 billion to $3.540 billion-$3.570…
- benzinga.com Bruker Q2 Adj. EPS $0.49 Beats $0.39 Estimate, Sales $838.500M Miss $853.543M Estimate Bruker (NASDAQ:BRKR) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.39 by 25.64 percent. This is a 53.12 percent increase over earnings of $0.32 per…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers iTonic Holdings (NASDAQ:ITOC) stock increased by 8.1% to $0.3 during Friday's after-market session. The market value of their outstanding shares is at $5.1 million. Advanced Biomed…
benzinga.com Bruker Acquires The DISQVER Clinical Metagenomics Platform From Noscendo; Financial Terms Not Disclosed The DISQVER® platform provides advanced bioinformatics and reporting to support rapid and comprehensive WGS analysis directly from cell-free human blood samplesDISQVER® enables metagenomic…- benzinga.com Citigroup Maintains Neutral on Bruker, Raises Price Target to $60 Citigroup analyst Patrick Donnelly maintains Bruker (NASDAQ:BRKR) with a Neutral and raises the price target from $44 to $60.
- benzinga.com Leerink Partners Maintains Outperform on Bruker, Raises Price Target to $70 Leerink Partners analyst Puneet Souda maintains Bruker (NASDAQ:BRKR) with a Outperform and raises the price target from $60 to $70.
- benzinga.com Guggenheim Maintains Buy on Bruker, Raises Price Target to $70 Guggenheim analyst Subbu Nambi maintains Bruker (NASDAQ:BRKR) with a Buy and raises the price target from $50 to $70.
- benzinga.com Barclays Maintains Overweight on Bruker, Raises Price Target to $60 Barclays analyst Luke Sergott maintains Bruker (NASDAQ:BRKR) with a Overweight and raises the price target from $53 to $60.
- benzinga.com Bruker Corp Files Prospectus For Mixed Shelf Offering, Size Not Disclosed Bruker CorporationCommon StockPreferred StockDebt SecuritiesWarrantsUnitsDepositary SharesSubscription RightsPurchase ContractsFrom time to time, we may offer and sell any combination of the…
- benzinga.com Bruker's Microbiology & Infection Diagnostic Division Showcases Expanding Portfolio, Innovations Throughout Microbial Identification, Sepsis Diagnostics, Molecular Testing, And NGS Workflows At ASM Microbe 2026, Bruker Corporation's (Nasdaq: BRKR) Microbiology & Infection Diagnostics (BMID) division is demonstrating its expanding portfolio and innovations across microbial identification,…
- benzinga.com At ASMS, Bruker Launches TimsMRMS System, Focused On Trapped Ion Mobility Separation To Ultra-high-resolution Magnetic Resonance Mass Spectrometry Bruker Also Launches Two Novel Mass Spectrometry Systems for Unique Applications in Energy Industry Research, and in Semiconductor ManufacturingLaunch of eXtreme 10M resolution novel timsMRMS™ mass…
- benzinga.com Bruker Announces Commissioning Of BioSpec 18 Tesla Preclinical MRI At Champalimaud Foundation In Lisbon, Portugal World's highest-field MRI system provides leading disease biology research capabilitiesBruker Corporation announced the commissioning of a novel BioSpec™ 18 Tesla preclinical MRI, the world's…
- benzinga.com UBS Maintains Neutral on Bruker, Raises Price Target to $45 UBS analyst Dan Leonard maintains Bruker (NASDAQ:BRKR) with a Neutral and raises the price target from $40 to $45.
- benzinga.com Citigroup Maintains Neutral on Bruker, Raises Price Target to $44 Citigroup analyst Patrick Donnelly maintains Bruker (NASDAQ:BRKR) with a Neutral and raises the price target from $40 to $44.
- benzinga.com TD Cowen Maintains Hold on Bruker, Raises Price Target to $45 TD Cowen analyst Kyle Boucher maintains Bruker (NASDAQ:BRKR) with a Hold and raises the price target from $43 to $45.
- benzinga.com Barclays Maintains Overweight on Bruker, Raises Price Target to $53 Barclays analyst Luke Sergott maintains Bruker (NASDAQ:BRKR) with a Overweight and raises the price target from $45 to $53.
benzinga.com Earnings Scheduled For May 6, 2026 
benzinga.com Full Transcript: Bruker Q1 2026 Earnings Call - benzinga.com Bruker Affirms FY2026 Adj EPS Guidance of $2.10-$2.15 vs $2.12 Est; Affirms FY2026 Sales Guidance of $3.570B-$3.600B vs $3.581B Est Bruker (NASDAQ:BRKR) affirms FY2026 Adj EPS guidance from $2.10-$2.15 to $2.10-$2.15 vs $2.12 analyst estimate. Affirms FY2026 sales outlook from $3.570 billion-$3.600 billion to $3.570…
- benzinga.com Bruker Q1 Adj. EPS $0.31 Beats $0.23 Estimate, Sales $823.400M Beat $796.352M Estimate Bruker (NASDAQ:BRKR) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.23 by 34.78 percent. This is a 34.04 percent decrease over earnings of $0.47 per…
- benzinga.com Bruker Announces Key Portfolio Improvements Across Microbial Identification, Outbreak Analysis And Reflex Next‑Generation Sequencing Typing MALDI Biotyper® (MBT): Launch of proprietary MBT Easy T® Kit for consistent sample transfer to MALDI target platesMALDI Biotyper®: Expansion of reference libraries to more than 5,300 species, spanning
- benzinga.com Barclays Maintains Overweight on Bruker, Lowers Price Target to $45 Barclays analyst Luke Sergott maintains Bruker (NASDAQ:BRKR) with a Overweight and lowers the price target from $50 to $45.
- benzinga.com Bruker Introduces New Nuclear Magnetic Resonance Products And Workflow Solutions To Expand Performance, Sensitivity And Automation The introductions span console electronics, quantitative chemistry, benchtop FT-NMR, solid-state and dissolution Dynamic Nuclear Polarization (DNP), and digital workflows that support reproducible,…
- benzinga.com Bruker Speeds Up Chip Research Tools as Semiconductor Tech Gets More Complex, Expands NanoIR Technology to Support Next-Gen Chip Development Bruker Corporation (NASDAQ:BRKR) today announced accelerated development of its photothermal AFM-IR spectroscopy capabilities to address research challenges facing the semiconductor industry as…
- benzinga.com Guggenheim Maintains Buy on Bruker, Lowers Price Target to $50 Guggenheim analyst Subbu Nambi maintains Bruker (NASDAQ:BRKR) with a Buy and lowers the price target from $58 to $50.
- benzinga.com Bruker Launches timsOmni Functional Proteomics 2.0 Workflows With OmniScape And GlycoScape Software For Drug Discovery Insights Novel timsOmni workflows enable deeper functional characterization of proteoforms and PTMs, leveraging multi-stage, ultra-sensitive trapped eXd molecular fragmentationBruker ProteoScape™ expands…
benzinga.com Forecasting The Future: 15 Analyst Projections For Bruker